Analysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes

Imagem de Miniatura
Arquivos
art_PASSERO_Analysis_of_the_protective_potential_of_antigens_released_2012.PDF (500.22 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
MARQUES, Claudia
VALE-GATO, Ines
SANTOS-GOMES, Gabriela
Citação
ARCHIVES OF DERMATOLOGICAL RESEARCH, v.304, n.1, p.47-55, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Leishmania (Viannia) shawi causes cutaneous lesions in humans. Parasite antigens conferring significant protection against American tegumentar leishmaniosis (ATL) might be important for the development of effective vaccine. Therefore, this work evaluates the protective effect of antigenic fractions released by L. shawi. Antigens released by promastigotes to culture medium were concentrated and isolated by SDS-PAGE. The three main fractions LsPass1 (>75 kDa), LsPass2 (75-50 kDa) and LsPass3 (<50 kDa) were electro-eluted according with their molecular mass. Immunized BALB/c mice were challenged with L. shawi promastigotes and the course of infection monitored during 5 weeks. LsPass1-challenged mice showed no protection, however, a strong degree of protection associated to smaller lesions and high expression of IFN-gamma and TNF-alpha by CD4(+) T, CD8(+) T and double negative CD4CD8 cells was achieved in LsPass3-challenged mice. Furthermore, LsPass2-challenged mice showed an intermediated degree of protection associated to high levels of IFN-gamma, IL-4 and IL-10 mRNA. In spite of increased expression of IFN-gamma and TNF-alpha, high amounts of IL-4 and IL-10 mRNA were also detected in LsPass3-challenged mice indicating a possible contribution of these cytokines for the persistence of a residual number of parasites that may be important in inducing long-lasting immunity. Therefore, LsPass3 seems to be an interesting alternative that should be considered in the development of an effective vaccine against ATL.
Palavras-chave
Leishmania shawi, Released antigens, Immunization
URI
https://observatorio.fm.usp.br/handle/OPI/1002
Referências
  1. Bogdan C, 2008, CELL MICROBIOL, V10, P1221, DOI 10.1111/j.1462-5822.2008.01146.x
  2. Brito MEF, 2009, TROP MED INT HEALTH, V14, P1278, DOI 10.1111/j.1365-3156.2009.02361.x
  3. Carneiro FP, 2009, PARASITE IMMUNOL, V31, P646, DOI 10.1111/j.1365-3024.2009.01148.x
  4. Chen GJ, 2009, AM J PATHOL, V175, P1086, DOI 10.2353/ajpath.2009.080488
  5. Darrah PA, 2010, J EXP MED, V207, P1421, DOI 10.1084/jem.20092532
  6. Dunning O, 2009, BIOSCI HORIZ, V2, P73
  7. Filippi CM, 2008, DIABETES, V57, P2684, DOI 10.2337/db08-0609
  8. Ivory C, 2004, GENET VACCINES THER, V2, P17, DOI 10.1186/1479-0556-2-17
  9. Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008
  10. Kaufmann SHE, 1999, IMMUNOL LETT, V65, P81, DOI 10.1016/S0165-2478(98)00128-X
  11. KREUTZER RD, 1991, AM J TROP MED HYG, V44, P662
  12. LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
  13. LAINSON R, 1989, ANN PARASIT HUM COMP, V64, P200
  14. LAINSON R, 1989, ANN PARASIT HUM COMP, V64, P3
  15. Lemesre JL, 2007, VACCINE, V25, P4223, DOI 10.1016/j.vaccine.2007.02.083
  16. Lemesre JL, 2005, VACCINE, V23, P2825, DOI 10.1016/j.vaccine.2004.11.061
  17. LIEW FY, 1990, J IMMUNOL, V145, P4306
  18. Nagill R, 2009, PARASITOL INT, V58, P359, DOI 10.1016/j.parint.2009.07.008
  19. Naundorf S, 2009, EUR J IMMUNOL, V39, P1066, DOI 10.1002/eji.200838773
  20. Novoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x
  21. O'Daly JA, 2010, ARCH DERMATOL RES, V302, P95, DOI 10.1007/s00403-009-0992-0
  22. O'Daly JA, 2009, ARCH DERMATOL RES, V301, P411, DOI 10.1007/s00403-009-0940-z
  23. O'Daly JA, 2010, ARCH DERMATOL RES, V302, P567, DOI 10.1007/s00403-009-1026-7
  24. O'Daly JA, 2009, ARCH DERMATOL RES, V301, P1, DOI 10.1007/s00403-008-0883-9
  25. O'Daly JA, 2011, ARCH DERMATOL RES, V303, P399, DOI 10.1007/s00403-011-1133-0
  26. Okwor I, 2008, IMMUNOL RES, V41, P123, DOI 10.1007/s12026-008-8016-2
  27. Passero LFD, 2009, PARASITOL RES, V105, P1741, DOI 10.1007/s00436-009-1614-7
  28. Passero LFD, 2010, PARASITOL INT, V59, P159, DOI 10.1016/j.parint.2009.12.010
  29. Passero LFD, 2010, APMIS, V118, P973, DOI 10.1111/j.1600-0463.2010.02679.x
  30. Rodrigues OR, 2009, IMMUNOBIOLOGY, V214, P101, DOI 10.1016/j.imbio.2008.07.001
  31. Rodrigues OR, 2006, CELL IMMUNOL, V243, P118, DOI 10.1016/j.cellimm.2007.01.005
  32. Rodriguez-Cortees A, 2007, VACCINE, V25, P7962, DOI 10.1016/j.vaccine.2007.08.023
  33. Rosa R, 2005, EXP PARASITOL, V109, P106, DOI 10.1016/j.exppara.2004.11.008
  34. Rosa R, 2007, VACCINE, V25, P4525, DOI 10.1016/j.vaccine.2007.03.003
  35. Santarem N, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/85154
  36. Shanmugasundaram R, 2010, VET IMMUNOL IMMUNOP, V137, P161, DOI 10.1016/j.vetimm.2010.04.017
  37. SHAW JJ, 1991, ANN PARASIT HUM COMP, V66, P243
  38. Silveira FT, 2004, MEM I OSWALDO CRUZ, V99, P239, DOI 10.1590/S0074-02762004000300001
  39. Silveira FT, 2002, PARASITE, V9, P43
  40. Souza-Lemos C, 2008, J PATHOL, V216, P375, DOI 10.1002/path.2403
  41. Taylor AW, 2009, J LEUKOCYTE BIOL, V85, P29, DOI 10.1189/jlb.0708415
  42. Tonui WK, 2004, INFECT IMMUN, V72, P5654, DOI 10.1128/IAI.72.10.5654-5661.2004
  43. Wolff J, 1990, SCIENCE, V1247, P1465

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - LIM/50